These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


281 related items for PubMed ID: 20600570

  • 1. Development and preclinical evaluation of a new F(ab')₂ antitoxin against botulinum neurotoxin serotype A.
    Yu YZ, Zhang SM, Wang WB, Du Y, Zhu HQ, Wang RL, Zhou XW, Lin JB, Wang S, Yu WY, Huang PT, Sun ZW.
    Biochimie; 2010 Oct; 92(10):1315-20. PubMed ID: 20600570
    [Abstract] [Full Text] [Related]

  • 2. Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F.
    Yu YZ, Zhang SM, Ma Y, Zhu HQ, Wang WB, Du Y, Zhou XW, Wang RL, Wang S, Yu WY, Huang PT, Sun ZW.
    Clin Immunol; 2010 Nov; 137(2):271-80. PubMed ID: 20696619
    [Abstract] [Full Text] [Related]

  • 3. Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E.
    Shi DY, Liu FJ, Mao YY, Cui RT, Lu JS, Yu YZ, Dong XJ, Yang ZX, Sun ZW, Pang XB.
    Hum Vaccin Immunother; 2020 Nov; 16(1):100-108. PubMed ID: 31210561
    [Abstract] [Full Text] [Related]

  • 4. Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs.
    Shi DY, Lu JS, Mao YY, Liu FJ, Wang R, Du P, Yu S, Yu YZ, Yang ZX.
    Appl Microbiol Biotechnol; 2023 May; 107(10):3205-3216. PubMed ID: 37058230
    [Abstract] [Full Text] [Related]

  • 5. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins.
    Barash JR, Arnon SS.
    J Infect Dis; 2014 Jan 15; 209(2):183-91. PubMed ID: 24106296
    [Abstract] [Full Text] [Related]

  • 6. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice.
    Lu J, Guo Z, Pan X, Wang G, Zhang D, Li Y, Tan B, Ouyang L, Yu X.
    Respir Res; 2006 Mar 23; 7(1):43. PubMed ID: 16553963
    [Abstract] [Full Text] [Related]

  • 7. Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.
    Fan Y, Barash JR, Lou J, Conrad F, Marks JD, Arnon SS.
    J Infect Dis; 2016 May 15; 213(10):1606-14. PubMed ID: 26936913
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine.
    Yu YZ, Li N, Wang RL, Zhu HQ, Wang S, Yu WY, Sun ZW.
    Clin Vaccine Immunol; 2008 Dec 15; 15(12):1819-23. PubMed ID: 18845829
    [Abstract] [Full Text] [Related]

  • 9. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
    Moreira C, da Cunha CE, Moreira GM, Mendonça M, Salvarani FM, Moreira ÂN, Conceição FR.
    Anaerobe; 2016 Aug 15; 40():58-62. PubMed ID: 27236078
    [Abstract] [Full Text] [Related]

  • 10. Botulinum type A toxin neutralisation by specific IgG and its fragments: a comparison of mouse systemic toxicity and local flaccid paralysis assays.
    Jones RG, Alsop TA, Hull R, Tierney R, Rigsby P, Holley J, Sesardic D.
    Toxicon; 2006 Sep 01; 48(3):246-54. PubMed ID: 16870221
    [Abstract] [Full Text] [Related]

  • 11. Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species.
    Atassi MZ, Dolimbek BZ, Hayakari M, Middlebrook JL, Whitney B, Oshima M.
    J Protein Chem; 1996 Oct 01; 15(7):691-700. PubMed ID: 8968960
    [Abstract] [Full Text] [Related]

  • 12. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate.
    Yu YZ, Li N, Zhu HQ, Wang RL, Du Y, Wang S, Yu WY, Sun ZW.
    Vaccine; 2009 May 11; 27(21):2816-22. PubMed ID: 19428892
    [Abstract] [Full Text] [Related]

  • 13. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.
    Rani S, Ponmariappan S, Sharma A, Kamboj DV, Jain AK.
    Protein Pept Lett; 2017 May 11; 24(6):495-502. PubMed ID: 28260503
    [Abstract] [Full Text] [Related]

  • 14. Exposure-Response Modeling and Simulation to Support Human Dosing of Botulism Antitoxin Heptavalent Product.
    Beliveau M, Anderson D, Barker D, Kodihalli S, Simard E, Hall C, Richardson JS.
    Clin Pharmacol Ther; 2022 Jul 11; 112(1):171-180. PubMed ID: 35467014
    [Abstract] [Full Text] [Related]

  • 15. Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism.
    Webb RP, Smith TJ, Smith LA, Wright PM, Guernieri RL, Brown JL, Skerry JC.
    Toxins (Basel); 2017 Sep 03; 9(9):. PubMed ID: 28869522
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.
    Gil LA, da Cunha CE, Moreira GM, Salvarani FM, Assis RA, Lobato FC, Mendonça M, Dellagostin OA, Conceição FR.
    PLoS One; 2013 Sep 03; 8(7):e69692. PubMed ID: 23936080
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic efficacy of equine botulism antitoxin in Rhesus macaques.
    Kodihalli S, Emanuel A, Takla T, Hua Y, Hobbs C, LeClaire R, O'Donnell DC.
    PLoS One; 2017 Sep 03; 12(11):e0186892. PubMed ID: 29166654
    [Abstract] [Full Text] [Related]

  • 19. Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt.
    Hibbs RG, Weber JT, Corwin A, Allos BM, Abd el Rehim MS, Sharkawy SE, Sarn JE, McKee KT.
    Clin Infect Dis; 1996 Aug 03; 23(2):337-40. PubMed ID: 8842274
    [Abstract] [Full Text] [Related]

  • 20. A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin.
    Maslanka SE, Lúquez C, Dykes JK, Tepp WH, Pier CL, Pellett S, Raphael BH, Kalb SR, Barr JR, Rao A, Johnson EA.
    J Infect Dis; 2016 Feb 01; 213(3):379-85. PubMed ID: 26068781
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 15.